Medicare Payment Increase in Final Budget Reconciliation Bill
The bill includes a 2.5% increase to the Medicare Physician Fee Schedule for calendar year 2026.
Read moreMain Content
ACR Informs Congress on AI Oversight, Use and Innovation
May 9, 2024
The American College of Radiology® (ACR®) responded to a targeted request for information from U.S. Rep. Ami Bera, MD, (CA-6), a member of the bipartisan House Task Force on Artificial Intelligence (AI), regarding the state of health care artificial intelligence (AI). Rep. Bera’s RFI included an extensive list of questions focused on various aspects of healthcare AI oversight, implementation, use and innovation.
ACR highlighted examples of real-world applications of healthcare AI and recommended ways to enhance product transparency and oversight mechanisms moving forward, including leveraging public-private partnerships. The College provided concepts that would be important in any future value-based payment approach looking at ensuring quality implementation, governance and use of high-value AI tools. ACR noted that not all currently reimbursed uses of AI are adding value to patients or the health system.
ACR also highlighted novel oversight questions posed by foundation models/generative AI used to enable higher risk functions such as diagnosis or treatment. The College noted the U.S. Food and Drug Administration may benefit from expanded authorities to meet future regulatory challenges and opportunities.
For more information about ACR’s AI-related programs and initiatives, visit the ACR Data Science Institute website. For questions about the ACR comment submission or AI oversight policy, contact Michael Peters, ACR Senior Government Affairs Director.
ACR highlighted examples of real-world applications of healthcare AI and recommended ways to enhance product transparency and oversight mechanisms moving forward, including leveraging public-private partnerships. The College provided concepts that would be important in any future value-based payment approach looking at ensuring quality implementation, governance and use of high-value AI tools. ACR noted that not all currently reimbursed uses of AI are adding value to patients or the health system.
ACR also highlighted novel oversight questions posed by foundation models/generative AI used to enable higher risk functions such as diagnosis or treatment. The College noted the U.S. Food and Drug Administration may benefit from expanded authorities to meet future regulatory challenges and opportunities.
For more information about ACR’s AI-related programs and initiatives, visit the ACR Data Science Institute website. For questions about the ACR comment submission or AI oversight policy, contact Michael Peters, ACR Senior Government Affairs Director.
Related ACR News
CMS Announces Prior Authorization Test Model
WiSer is a six-year program that will begin in six states on January 1, 2026. It will introduce prior authorization using AI technology for a select number of services, including some IR procedures.
Read moreSupreme Court Upholds Preventive Services Coverage
ACR commends the Supreme Court’s ruling affirming the constitutionality of the structure and appointment process of the U.S. Preventive Services Task Force.
Read more